{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:50:21Z","timestamp":1790801421271,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12549-5","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:55:32Z","timestamp":1786359332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities"],"prefix":"10.1007","volume":"53","author":[{"given":"Rijuta Dhanraj","family":"Mukim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yama","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Evola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-9857","authenticated-orcid":false,"given":"Mayur S.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"12549_CR1","unstructured":"Collins L, Costello RA (2024) Glucagon-Like Peptide-1 Receptor Agonists, in StatPearls. Treasure Island (FL). https:\/\/pubmed.ncbi.nlm.nih.gov\/31855395\/"},{"key":"12549_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","volume":"86","author":"A Moiz","year":"2025","unstructured":"Moiz A et al (2025) The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine 86:103363. https:\/\/www.mdpi.com\/1467-3045\/47\/4\/285","journal-title":"EClinicalMedicine"},{"issue":"1","key":"12549_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00011-025-02166-6","volume":"75","author":"V Evola","year":"2026","unstructured":"Evola V, Parmar MS (2026) Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide. Inflamm Res 75(1):13. https:\/\/link.springer.com\/article\/10.1007\/s00011-025-02166-6","journal-title":"Inflamm Res"},{"issue":"5","key":"12549_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47040285","volume":"22","author":"A Roy","year":"2025","unstructured":"Roy A, Dawson VL, Dawson TM (2025) From metabolism to mind: the expanding role of the GLP-1 receptor in neurotherapeutics. Neurotherapeutics 22(5):e00712. https:\/\/doi.org\/10.3390\/cimb47040285","journal-title":"Neurotherapeutics"},{"issue":"6","key":"12549_CR5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.4103\/1673-5374.358621","volume":"18","author":"LF Hoffmann","year":"2023","unstructured":"Hoffmann LF et al (2023) Neural regeneration research model to be explored: SH-SY5Y human neuroblastoma cells. Neural Regen Res 18(6):1265\u20131266. https:\/\/doi.org\/10.4103\/1673-5374.358621","journal-title":"Neural Regen Res"},{"key":"12549_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.neuroscience.2024.11.022","volume":"563","author":"ZJ Wang","year":"2024","unstructured":"Wang ZJ et al (2024) Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP\/PS1\/tau mice. Neuroscience 563:222\u2013234. https:\/\/doi.org\/10.1016\/j.neuroscience.2024.11.022","journal-title":"Neuroscience"},{"key":"12549_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512486","author":"G Plascencia-Villa","year":"2023","unstructured":"Plascencia-Villa G, Perry G (2023) Exploring molecular targets for mitochondrial therapies in neurodegenerative diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241512486","journal-title":"Int J Mol Sci"},{"issue":"1","key":"12549_CR8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1007\/s12035-024-04285-3","volume":"62","author":"A Ortega","year":"2025","unstructured":"Ortega A, Chernicki B, Ou G, Parmar MS (2025) From lab bench to hope: emerging gene therapies in clinical trials for Alzheimer's disease. Mol Neurobiol 62(1):1112\u20131135. https:\/\/doi.org\/10.1007\/s12035-024-04285-3","journal-title":"Mol Neurobiol"},{"issue":"2","key":"12549_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/procel\/pwae026","volume":"16","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Wang X (2025) Alzheimer\u2019s disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell 16(2):83\u2013120. https:\/\/doi.org\/10.1093\/procel\/pwae026","journal-title":"Protein Cell"},{"key":"12549_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/1179573520907397","author":"KG Yiannopoulou","year":"2020","unstructured":"Yiannopoulou KG, Papageorgiou SG (2020) Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis. https:\/\/doi.org\/10.1177\/1179573520907397","journal-title":"J Cent Nerv Syst Dis"},{"issue":"5","key":"12549_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0045-1808082","volume":"83","author":"R Nitrini","year":"2025","unstructured":"Nitrini R, Studart-Neto A (2025) Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer\u2019s disease. Arq Neuropsiquiatr 83(5):1\u20135. https:\/\/doi.org\/10.1055\/s-0045-1808082","journal-title":"Arq Neuropsiquiatr"},{"issue":"1","key":"12549_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J et al (2024) Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer\u2019s Disease. BioDrugs 38(1):5\u201322. https:\/\/doi.org\/10.1007\/s40259-023-00633-2","journal-title":"BioDrugs"},{"key":"12549_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2025-004902","author":"M Sun","year":"2025","unstructured":"Sun M et al (2025) Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes. BMJ Open Diabetes Res Care. https:\/\/doi.org\/10.1136\/bmjdrc-2025-004902","journal-title":"BMJ Open Diabetes Res Care"},{"key":"12549_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050614","author":"M Urkon","year":"2025","unstructured":"Urkon M et al (2025) Antidiabetic GLP-1 receptor agonists have neuroprotective properties in experimental animal models of Alzheimer\u2019s disease. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph18050614","journal-title":"Pharmaceuticals (Basel)"},{"key":"12549_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117540","volume":"180","author":"Y Zhang","year":"2024","unstructured":"Zhang Y et al (2024) Semaglutide ameliorates Alzheimer\u2019s disease and restores oxytocin in APP\/PS1 mice and human brain organoid models. Biomed Pharmacother 180:117540. https:\/\/doi.org\/10.1016\/j.biopha.2024.117540","journal-title":"Biomed Pharmacother"},{"key":"12549_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177305","volume":"991","author":"NN Elbadawy","year":"2025","unstructured":"Elbadawy NN et al (2025) The GLP-1 agonist semaglutide ameliorates cognitive regression in P301S tauopathy mice model via autophagy\/ACE2\/SIRT1\/FOXO1-mediated microglia polarization. Eur J Pharmacol 991:177305. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177305","journal-title":"Eur J Pharmacol"},{"key":"12549_CR17","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.molmet.2024.102019","volume":"89","author":"L Forny Germano","year":"2024","unstructured":"Forny Germano L et al (2024) The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice. Mol Metab 89:102019. https:\/\/doi.org\/10.1016\/j.molmet.2024.102019","journal-title":"Mol Metab"},{"issue":"6","key":"12549_CR18","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3390\/biomedicines14061257","volume":"14","author":"AV Stavrovskaya","year":"2026","unstructured":"Stavrovskaya AV et al (2026) Impact of Semaglutide on Hippocampal Injury in a Streptozotocin-Induced Model of Alzheimer\u2019s Disease. Biomedicines 14(6):1257. https:\/\/doi.org\/10.3390\/biomedicines14061257","journal-title":"Biomedicines"},{"key":"12549_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-026-05568-0","author":"Y Yuan","year":"2026","unstructured":"Yuan Y et al (2026) Semaglutide ameliorates neuroinflammation and cognitive impairment in APP\/PS1 mice. Mol Cell Biochem. https:\/\/doi.org\/10.1007\/s11010-026-05568-0","journal-title":"Mol Cell Biochem"},{"issue":"12","key":"12549_CR20","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.3390\/ijms27125311","volume":"27","author":"L Shahabian","year":"2026","unstructured":"Shahabian L et al (2026) Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice. Int J Mol Sci 27(12):5311. https:\/\/doi.org\/10.3390\/ijms27125311","journal-title":"Int J Mol Sci"},{"key":"12549_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jocn.2020.09.054","volume":"81","author":"YF Chang","year":"2020","unstructured":"Chang YF et al (2020) Semaglutide-mediated protection against A\u03b2 correlated with enhancement of autophagy and inhibition of apotosis. J Clin Neurosci 81:234\u2013239. https:\/\/doi.org\/10.1016\/j.jocn.2020.09.054","journal-title":"J Clin Neurosci"},{"key":"12549_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109716","volume":"240","author":"ZJ Wang","year":"2023","unstructured":"Wang ZJ et al (2023) Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway. Neuropharmacology 240:109716. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109716","journal-title":"Neuropharmacology"},{"issue":"2","key":"12549_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.neuropharm.2023.109716","volume":"105","author":"Y Zhai","year":"2025","unstructured":"Zhai Y et al (2025) Semaglutide improves cognitive function and neuroinflammation in APP\/PS1 transgenic mice by activating AMPK and inhibiting TLR4\/NF-\u03baB pathway. J Alzheimer\u2019s Disease 105(2):416\u2013432. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109716","journal-title":"J Alzheimer\u2019s Disease"},{"issue":"1","key":"12549_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70200","volume":"12","author":"P Scheltens","year":"2026","unstructured":"Scheltens P et al (2026) Baseline characteristics from evoke and evoke+: two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Dement (N Y) 12(1):e70200. https:\/\/doi.org\/10.1002\/trc2.70200","journal-title":"Alzheimers Dement (N Y)"},{"key":"12549_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00459-9","author":"JL Cummings","year":"2026","unstructured":"Cummings JL et al (2026) Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer\u2019s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(26)00459-9","journal-title":"Lancet"},{"issue":"11_Supplement_1","key":"12549_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000216961","volume":"106","author":"K Frederiksen","year":"2026","unstructured":"Frederiksen K et al (2026) Effects of semaglutide on Alzheimer\u2019s disease-related biological processes: results from a biofluid biomarker and multiomics immunophenotyping phase 3 study in patients with early Alzheimer\u2019s disease after 12 weeks of treatment (S1.008). Neurology 106(11_Supplement_1):4165. https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0000000000216961","journal-title":"Neurology"},{"key":"12549_CR27","volume-title":"18th Clinical Trials on Alzheimer\u2019s Disease (CTAD 2025)","author":"P Johannsen","year":"2025","unstructured":"Johannsen P et al (2025) Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer\u2019s Disease After 12 Weeks of Subcutaneous Treatment. 18th Clinical Trials on Alzheimer\u2019s Disease (CTAD 2025). Novo Nordisk, San Diego, US https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0000000000216104"},{"key":"12549_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.mad.2023.111898","author":"T Davidy","year":"2023","unstructured":"Davidy T et al (2023) A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- study rationale and design. Mech Ageing Dev. https:\/\/doi.org\/10.1016\/j.mad.2023.111898","journal-title":"Mech Ageing Dev"},{"issue":"12","key":"12549_CR29","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W et al (2024) Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimers Dement 20(12):8661\u20138672. https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.14313","journal-title":"Alzheimers Dement"},{"key":"12549_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2026.113083","author":"A Younis","year":"2026","unstructured":"Younis A et al (2026) Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: real world evidence from a retrospective cohort study. Diabetes Res Clin Pract. https:\/\/doi.org\/10.1016\/j.diabres.2026.113083","journal-title":"Diabetes Res Clin Pract"},{"key":"12549_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2026.109306","author":"AMP da Silva","year":"2026","unstructured":"da Silva AMP et al (2026) Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer\u2019s disease in type 2 diabetes: a real-world, retrospective cohort study. J Diabetes Complications. https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109306","journal-title":"J Diabetes Complications"},{"issue":"Pt 3","key":"12549_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113537","volume":"143","author":"N Siddeeque","year":"2024","unstructured":"Siddeeque N et al (2024) Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study. Int Immunopharmacol 143(Pt 3):113537. https:\/\/doi.org\/10.1016\/j.intimp.2024.113537","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"12549_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41531-022-00410-y","volume":"8","author":"AW Willis","year":"2022","unstructured":"Willis AW et al (2022) Incidence of Parkinson disease in North America. NPJ Parkinsons Dis 8(1):170. https:\/\/doi.org\/10.1038\/s41531-022-00410-y","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"12549_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang L et al (2019) Semaglutide is Neuroprotective and Reduces \u03b1-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson\u2019s Disease. J Parkinsons Dis 9(1):157\u2013171. https:\/\/doi.org\/10.3233\/JPD-181503","journal-title":"J Parkinsons Dis"},{"key":"12549_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6813017","volume":"2022","author":"DX Liu","year":"2022","unstructured":"Liu DX et al (2022) Semaglutide protects against 6-OHDA toxicity by enhancing autophagy and inhibiting oxidative stress. Parkinsons Dis 2022:6813017. https:\/\/doi.org\/10.1155\/2022\/6813017","journal-title":"Parkinsons Dis"},{"key":"12549_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1428817","volume":"2022","author":"L Zhang","year":"2022","unstructured":"Zhang L et al (2022) DA5-CH and semaglutide protect against neurodegeneration and reduce \u03b1-synuclein levels in the 6-OHDA Parkinson\u2019s disease rat model. Parkinsons Dis 2022:1428817. https:\/\/doi.org\/10.1155\/2022\/1428817","journal-title":"Parkinsons Dis"},{"key":"12549_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","volume":"71","author":"L Zhang","year":"2018","unstructured":"Zhang L et al (2018) Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model. Neuropeptides 71:70\u201380. https:\/\/doi.org\/10.1016\/j.npep.2018.07.003","journal-title":"Neuropeptides"},{"issue":"9","key":"12549_CR38","doi-asserted-by":"publisher","first-page":"11919","DOI":"10.1007\/s00210-025-03920-7","volume":"398","author":"EA Salem","year":"2025","unstructured":"Salem EA et al (2025) Neuroprotective effects of semaglutide and metformin against rotenone-induced neurobehavioral changes in male diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 398(9):11919\u201311931. https:\/\/doi.org\/10.1007\/s00210-025-03920-7","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"12549_CR39","unstructured":"NCT03659682 (2018) Effect of GLPIR Stimulation on Neuroprotection and Inflammation in Parkinson\u2019s Disease. https:\/\/clinicaltrials.gov\/study\/NCT03659682"},{"issue":"3","key":"12549_CR40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1161\/CIRCRESAHA.116.308398","volume":"120","author":"AK Boehme","year":"2017","unstructured":"Boehme AK, Esenwa C, Elkind MS (2017) Stroke Risk Factors, Genetics, and Prevention. Circ Res 120(3):472\u2013495. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308398","journal-title":"Circ Res"},{"issue":"1","key":"12549_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5853\/jos.2022.02306","volume":"25","author":"O Mosenzon","year":"2023","unstructured":"Mosenzon O et al (2023) Diabetes and Stroke: What Are the Connections? J Stroke 25(1):26\u201338. https:\/\/doi.org\/10.5853\/jos.2022.02306","journal-title":"J Stroke"},{"key":"12549_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107748","volume":"158","author":"X Yang","year":"2019","unstructured":"Yang X et al (2019) The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology 158:107748. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107748","journal-title":"Neuropharmacology"},{"issue":"9","key":"12549_CR43","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/STROKEAHA.121.03777","volume":"53","author":"WD Strain","year":"2022","unstructured":"Strain WD et al (2022) Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke 53(9):2749\u20132757. https:\/\/doi.org\/10.1161\/STROKEAHA.121.03777","journal-title":"Stroke"},{"issue":"7","key":"12549_CR44","doi-asserted-by":"publisher","first-page":"e2521016","DOI":"10.1001\/jamanetworkopen.2025.21016","volume":"8","author":"HT Lin","year":"2025","unstructured":"Lin HT et al (2025) Neurodegeneration and stroke after semaglutide and tirzepatide in patients with diabetes and obesity. JAMA Netw Open 8(7):e2521016. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.21016","journal-title":"JAMA Netw Open"},{"issue":"1","key":"12549_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10571-025-01534-4","volume":"45","author":"I Pi\u0105tkowska-Chmiel","year":"2025","unstructured":"Pi\u0105tkowska-Chmiel I et al (2025) Beyond Diabetes: Semaglutide\u2019s Role in Modulating Mood Disorders through Neuroinflammation Pathways. Cell Mol Neurobiol 45(1):22. https:\/\/doi.org\/10.1007\/s10571-025-01534-4","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"12549_CR46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11481-024-10142-w","volume":"19","author":"IHR de Paiva","year":"2024","unstructured":"de Paiva IHR et al (2024) Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis. J Neuroimmune Pharmacol 19(1):36. https:\/\/doi.org\/10.1007\/s11481-024-10142-w","journal-title":"J Neuroimmune Pharmacol"},{"key":"12549_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111091","volume":"135","author":"MH Hussein","year":"2024","unstructured":"Hussein MH et al (2024) Semaglutide ameliorated autism-like behaviors and DNA repair efficiency in male BTBR mice by recovering DNA repair gene expression. Prog Neuropsychopharmacol Biol Psychiatry 135:111091. https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111091","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10130","key":"12549_CR48","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ et al (2018) Multiple sclerosis. Lancet 391(10130):1622\u20131636. https:\/\/doi.org\/10.1016\/S0140-6736(18)30481-1","journal-title":"Lancet"},{"key":"12549_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109647","volume":"115","author":"MA Sadek","year":"2023","unstructured":"Sadek MA et al (2023) Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: involvement of the PI3K\/Akt\/GSK-3\u03b2 pathway. Int Immunopharmacol 115:109647. https:\/\/doi.org\/10.1016\/j.intimp.2022.109647","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"12549_CR50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10072-024-07701-7","volume":"46","author":"M Udawatta","year":"2025","unstructured":"Udawatta M, Fidalgo N, Mateen FJ (2025) Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss. Neurol Sci 46(1):343\u2013349. https:\/\/doi.org\/10.1007\/s10072-024-07701-7","journal-title":"Neurol Sci"},{"key":"12549_CR51","unstructured":"Lovik K, Murr NI (2025) Seizure, in StatPearls. : Treasure Island (FL). https:\/\/pubmed.ncbi.nlm.nih.gov\/28613516\/"},{"key":"12549_CR52","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2021.5052","author":"L Wang","year":"2021","unstructured":"Wang L et al (2021) Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole\u2011kindled mice. Int J Mol Med. https:\/\/doi.org\/10.3892\/ijmm.2021.5052","journal-title":"Int J Mol Med"},{"issue":"1","key":"12549_CR53","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214509","volume":"106","author":"C-Y Cheng","year":"2026","unstructured":"Cheng C-Y et al (2026) Association between GLP-1 receptor agonist use and epilepsy risk in type 2 diabetes. Neurology 106(1):e214509. https:\/\/doi.org\/10.1212\/WNL.0000000000214509","journal-title":"Neurology"},{"issue":"1","key":"12549_CR54","doi-asserted-by":"publisher","first-page":"e218174","DOI":"10.1212\/WNL.0000000000218174","volume":"107","author":"Y Eun","year":"2026","unstructured":"Eun Y et al (2026) Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation. Neurology 107(1):e218174. https:\/\/doi.org\/10.1212\/WNL.0000000000218174","journal-title":"Neurology"},{"issue":"2","key":"12549_CR55","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/01658107.2023.2281433","volume":"48","author":"A Yiangou","year":"2024","unstructured":"Yiangou A et al (2024) The Impact of Valsalva Manoeuvres and Exercise on Intracranial Pressure and Cerebrovascular Dynamics in Idiopathic Intracranial Hypertension. Neuroophthalmology 48(2):122\u2013133. https:\/\/doi.org\/10.1080\/01658107.2023.2281433","journal-title":"Neuroophthalmology"},{"issue":"1","key":"12549_CR56","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-023-01631-z","volume":"24","author":"N Krajnc","year":"2023","unstructured":"Krajnc N et al (2023) Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain 24(1):89. https:\/\/doi.org\/10.1186\/s10194-023-01631-z","journal-title":"J Headache Pain"},{"key":"12549_CR57","unstructured":"NCT06027567 (2023) The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure (IIH:DUAL). https:\/\/clinicaltrials.gov\/study\/NCT06027567"},{"key":"12549_CR58","unstructured":"NCT06361823 (2024) An Exploratory Study Assessing the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment. https:\/\/clinicaltrials.gov\/study\/NCT06361823"},{"issue":"10","key":"12549_CR59","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1038\/s41433-025-03807-0","volume":"39","author":"L Kravetz","year":"2025","unstructured":"Kravetz L et al (2025) The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study. Eye (Lond) 39(10):2090\u20132095. https:\/\/doi.org\/10.1038\/s41433-025-03807-0","journal-title":"Eye (Lond)"},{"key":"12549_CR60","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.2020","author":"GS Sioutas","year":"2025","unstructured":"Sioutas GS et al (2025) GLP-1 receptor agonists in idiopathic intracranial hypertension. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2025.2020","journal-title":"JAMA Neurol"},{"issue":"1","key":"12549_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-13593-0","volume":"15","author":"N Dietz","year":"2025","unstructured":"Dietz N et al (2025) Obesity in chronic spinal cord injury is associated with poorer body composition and increased risk of cardiometabolic disease. Sci Rep 15(1):29073. https:\/\/doi.org\/10.1038\/s41598-025-13593-0","journal-title":"Sci Rep"},{"key":"12549_CR62","unstructured":"NCT03292315 (2017) The Efficacy of a Once Weekly Glucagon-Like Peptide-1 Agonist on Body Weight\/Composition and Metabolic Parameters in Persons With SCI. https:\/\/clinicaltrials.gov\/study\/NCT03292315"},{"key":"12549_CR63","unstructured":"NCT06706284 (2024) Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes. https:\/\/clinicaltrials.gov\/study\/NCT06706284"},{"key":"12549_CR64","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251351329","author":"W Wang","year":"2025","unstructured":"Wang W et al (2025) Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: a real-world target trial emulation study. J Alzheimers Dis. https:\/\/doi.org\/10.1177\/13872877251351329","journal-title":"J Alzheimers Dis"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12549-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12549-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12549-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:55:35Z","timestamp":1786359335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12549-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12549"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12549-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":1,"name":"Ethics","label":"Conflicts of interest\/Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required for this study.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"To refine the final written draft of the article, the author(s) utilized artificial intelligence (AI) software (Co-Pilot), solely for identifying and correcting grammatical errors and enhancing the overall readability of the final draft. After using this tool\/service, the author(s) reviewed and edited the content as needed and take (s) full responsibility for the content of the publication.","order":5,"name":"Ethics","label":"Statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1373"}}